IL9R

Summary

IL9R (interleukin 9 receptor, HGNC:6030) is a protein-coding gene on chromosome Xq28 and Yq12, encoding Interleukin-9 receptor (Q01113). Plays an important role in the immune response against parasites by acting as a receptor of IL9.

The protein encoded by this gene is a cytokine receptor that specifically mediates the biological effects of interleukin 9 (IL9). The functional IL9 receptor complex requires this protein as well as the interleukin 2 receptor, gamma (IL2RG), a common gamma subunit shared by the receptors of many different cytokines. The ligand binding of this receptor leads to the activation of various JAK kinases and STAT proteins, which connect to different biologic responses. This gene is located at the pseudoautosomal regions of X and Y chromosomes. Genetic studies suggested an association of this gene with the development of asthma. Multiple pseudogenes on chromosome 9, 10, 16, and 18 have been described. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 3581 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 101 total — 2 pathogenic
• MANE Select transcript: NM_002186

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6030
Approved symbol	IL9R
Name	interleukin 9 receptor
Location	Xq28 and Yq12
Locus type	gene with protein product
Status	Approved
Aliases	CD129
Ensembl gene	ENSG00000124334
Ensembl biotype	protein_coding
OMIM	300007
Entrez	3581

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000244174, ENST00000369423, ENST00000489233, ENST00000494962, ENST00000858259

RefSeq mRNA: 2 — MANE Select: NM_002186 NM_002186, NM_176786

CCDS: CCDS14771, CCDS59180

Canonical transcript exons

ENST00000244174 — 9 exons

Exon	Start	End
ENSE00000846398	156004420	156004565
ENSE00001325991	156002906	156003019
ENSE00001614034	156009816	156010817
ENSE00001637342	156006083	156006188
ENSE00001741000	156005278	156005479
ENSE00001742205	156003449	156003560
ENSE00001800113	156003677	156003855
ENSE00003659134	156007523	156007607
ENSE00003693591	155997696	155997787

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 78.51.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1992 / max 235.9477, expressed in 14 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198224	0.1057	8
198225	0.0445	10
198223	0.0319	6
198226	0.0171	4

Top tissues by expression

148 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.51	gold quality
lymph node	UBERON:0000029	74.21	gold quality
granulocyte	CL:0000094	72.68	gold quality
vermiform appendix	UBERON:0001154	72.15	gold quality
thymus	UBERON:0002370	71.21	silver quality
lower esophagus mucosa	UBERON:0035834	71.20	gold quality
spleen	UBERON:0002106	70.71	gold quality
right uterine tube	UBERON:0001302	69.71	gold quality
rectum	UBERON:0001052	68.99	gold quality
small intestine Peyer’s patch	UBERON:0003454	68.46	gold quality
urinary bladder	UBERON:0001255	68.33	gold quality
blood	UBERON:0000178	67.84	gold quality
mucosa of transverse colon	UBERON:0004991	67.71	gold quality
gall bladder	UBERON:0002110	67.47	gold quality
small intestine	UBERON:0002108	67.41	gold quality
tonsil	UBERON:0002372	64.79	gold quality
leukocyte	CL:0000738	62.31	gold quality
upper lobe of left lung	UBERON:0008952	61.49	gold quality
monocyte	CL:0000576	61.37	gold quality
right lung	UBERON:0002167	61.36	gold quality
colonic epithelium	UBERON:0000397	60.91	gold quality
esophagus mucosa	UBERON:0002469	60.50	gold quality
transverse colon	UBERON:0001157	59.98	gold quality
vastus lateralis	UBERON:0001379	59.82	gold quality
quadriceps femoris	UBERON:0001377	59.78	gold quality
lung	UBERON:0002048	58.78	gold quality
bone marrow	UBERON:0002371	58.72	gold quality
intestine	UBERON:0000160	58.48	gold quality
epithelium of bronchus	UBERON:0002031	58.19	gold quality
smooth muscle tissue	UBERON:0001135	58.05	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-84	yes	259.71
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting IL9R, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-323A-5P	98.59	65.13	651
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-3085-5P	97.72	65.43	544
HSA-MIR-4475	97.36	66.95	761
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-216B-5P	97.16	66.76	1126
HSA-MIR-517-5P	97.13	68.43	781
HSA-MIR-6851-3P	95.73	65.11	688
HSA-MIR-6769A-3P	94.91	61.36	412

Literature-anchored findings (GeneRIF, showing 23)

• Human bronchial epithelium expresses interleukin-9 receptors. (PMID:11868823)
• variations in the IL9R gene may influence susceptibility to childhood wheezing and atopy, and data support the notion that different haplotypes may have sex specific influences (PMID:15591265)
• IL-9 and its receptor have roles in cell growth and malignant transformation of lymphoid cells associated with constitutive activation of the Jak/STAT pathway [review] (PMID:15621723)
• Variants in the IL4RA gene alone may not exert any major influence on susceptibility to asthma-related diseases in childhood, but in combination with other genes, such as IL9R, IL4RA may be an important gene for disease susceptibility (PMID:17083349)
• IL-9R alpha was expressed on human tonsillar B cells, with an ability to transduce signals through activation of signal transducer and activator of transcription 3 and 5. (PMID:17919707)
• primary ATL cells, via IL-9, support the action of IL-9Ralpha/CD14-expressing monocytes, which subsequently support the ex vivo spontaneous proliferation of malignant T cells (PMID:18339896)
• the preformed complexes between gamma c and IL-2Rbeta or IL-9Ralpha promote signaling by the JAK3 A572V mutant without ligand, identified in several human cancers. (PMID:18829468)
• IL-9Ralpha and IL-2Rbeta homodimers efficiently mediate constitutive activation of ALL-associated JAK1 mutants. (PMID:19139102)
• These results reveal a regulatory function for IFN-gamma and IL-10 on modulating the inducible IL-9Ralpha expression levels on peripheral blood neutrophils by T(H)2 cytokines. (PMID:19401191)
• There is an association of at least 2 X-chromosomal genes with rheumatoid arthritis: TIMP1 and IL9R. (PMID:19723899)
• analysis of IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in a Korean population (PMID:21371865)
• One of the identified peptide sequences corresponded to a fragment of the human interleukin-9 receptor alpha (IL-9Ralpha). (PMID:22638550)
• Our findings suggest that overexpression of IL-9R may contribute to the pathogenesis of diffuse large B-cell lymphoma (PMID:23638223)
• Mice with PU.1 deficiency in T cells were protected from colitis, whereas treatment with antibody to IL-9 suppressed colitis (PMID:24908389)
• Confocal microscopy and fluorescence resonance energy transfer experiments revealed nonrandom association of IL-9R with IL-2R/major histocompatibility complex glycoproteins at the surface of human T lymphoma cells. (PMID:25297818)
• Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease. (PMID:25421756)
• The findings indicated that IL-9R was constitutively expressed and exerted a tumor-promoting effect in hepatocellular carcinoma, whose expression level may be a useful biomarker of tumor invasiveness and patient clinical outcome. (PMID:26082242)
• Results show that silencing of the IL-9R gene alleviates the drug resistance of diffuse large B-cell lymphoma (DLBCL) cell lines that is induced by IL-9 suggesting that IL-9R is involved in chemotherapy drug resistance of DLBCL. (PMID:27364124)
• in PsA patients gammadelta T cells activation is driven prevalently by IL-9/IL-9R interaction, and not only by IL-23/IL-23R. Together these findings indicate gammadelta T cells and IL-9 as new players in the pathogenesis of PsA. (PMID:27543964)
• Thus the IL-9/IL-9R system is a new contributing factor in the cytokine network of psoriatic arthritis and rheumatoid arthritis. (PMID:30114630)
• Decreased placental IL9 and IL9R in preeclampsia impair trophoblast cell proliferation, invasion, and angiogenesis. (PMID:32329646)
• IL-9R Loss in Type 2 Innate Lymphoid Cells Reflects Treg Impairment in Patients With Mastocytosis. (PMID:35416152)
• IL-9 and IL-9 receptor expression in lymphocytes from bronchoalveolar lavage fluid of patients with interstitial lung disease. (PMID:35998415)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mpl	ENSDARG00000039222
mus_musculus	Il9r	ENSMUSG00000020279
rattus_norvegicus	Il9r	ENSRNOG00000020630

Paralogs (7): IL4R (ENSG00000077238), CSF2RB (ENSG00000100368), IL2RB (ENSG00000100385), IL21R (ENSG00000103522), MPL (ENSG00000117400), IL7R (ENSG00000168685), EPOR (ENSG00000187266)

Protein

Protein identifiers

Interleukin-9 receptor — Q01113 (reviewed: Q01113)

All UniProt accessions (1): Q01113

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the immune response against parasites by acting as a receptor of IL9.

Subunit / interactions. Interacts with IL9.

Subcellular location. Cell membrane. Secreted.

Domain organisation. The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box 1 motif is required for JAK interaction and/or activation.

Miscellaneous. The gene coding for this protein is located in the pseudoautosomal region 2 (PAR2) of X and Y chromosomes.

Similarity. Belongs to the type I cytokine receptor family. Type 4 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q01113-1	1	yes
Q01113-2	2
Q01113-3	3

RefSeq proteins (2): NP_002177, NP_789743 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003531	Hempt_rcpt_S_F1_CS	Conserved_site
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily

UniProt features (45 total): strand 15, helix 6, splice variant 5, sequence variant 5, glycosylation site 2, topological domain 2, short sequence motif 2, signal peptide 1, chain 1, sequence conflict 1, turn 1, transmembrane region 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7OX5	X-RAY DIFFRACTION	3.09

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01113-F1	64.30	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 117, 156

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8985947	Interleukin-9 signaling

MSigDB gene sets: 116 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOCC_CELL_SURFACE, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_B_CELL_MEDIATED_IMMUNITY, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN, GTGCCTT_MIR506, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, GOBP_ADAPTIVE_IMMUNE_RESPONSE, GOBP_IMMUNE_EFFECTOR_PROCESS, GOBP_ADAPTIVE_IMMUNE_RESPONSE_BASED_ON_SOMATIC_RECOMBINATION_OF_IMMUNE_RECEPTORS_BUILT_FROM_IMMUNOGLOBULIN_SUPERFAMILY_DOMAINS, YAGI_AML_WITH_11Q23_REARRANGED, KEGG_JAK_STAT_SIGNALING_PATHWAY

GO Biological Process (5): signal transduction (GO:0007165), immunoglobulin mediated immune response (GO:0016064), interleukin-9-mediated signaling pathway (GO:0038113), regulation of cell population proliferation (GO:0042127), cytokine-mediated signaling pathway (GO:0019221)

GO Molecular Function (4): interleukin-9 receptor activity (GO:0004919), interleukin-9 binding (GO:0019983), cytokine receptor activity (GO:0004896), protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), extracellular region (GO:0005576), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interleukin-2 family signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of cellular process	2
cytokine-mediated signaling pathway	2
cytokine binding	2
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
cellular response to stimulus	1
B cell mediated immunity	1
cellular response to interleukin-9	1
cell population proliferation	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
cytokine receptor activity	1
interleukin-9 binding	1
interleukin-9-mediated signaling pathway	1
growth factor binding	1
transmembrane signaling receptor activity	1
immune receptor activity	1
binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1

Protein interactions and networks

STRING

925 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL9R	IL9	P15248	968
IL9R	IL2RG	P31785	766
IL9R	SPRY3	O43610	756
IL9R	VAMP7	P51809	709
IL9R	CD38	P28907	661
IL9R	IL4	P05112	617
IL9R	IRF4	Q15306	603
IL9R	IL7	P13232	589
IL9R	IL2	P01585	585
IL9R	CCRL2	O00421	557
IL9R	CCR6	P51684	557
IL9R	VAMP1	P23763	549
IL9R	CCL17	Q92583	529
IL9R	ZBTB32	Q9Y2Y4	516
IL9R	CXCR5	P32302	509

IntAct

10 interactions, top by confidence:

A	B	Type	Score
YWHAZ	IL9R	psi-mi:“MI:0915”(physical association)	0.630
YWHAZ	IL9R	psi-mi:“MI:0914”(association)	0.630
YWHAZ	IL9R	psi-mi:“MI:0407”(direct interaction)	0.630
IL9R	RETSAT	psi-mi:“MI:0914”(association)	0.530
CRADD	IL9R	psi-mi:“MI:0915”(physical association)	0.370
IL9R	TMEM131L	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): LSR (Affinity Capture-MS), CCPG1 (Affinity Capture-MS), SARAF (Affinity Capture-MS), RETSAT (Affinity Capture-MS), DHRS7 (Affinity Capture-MS), DGCR2 (Affinity Capture-MS), TTC17 (Affinity Capture-MS), NETO2 (Affinity Capture-MS), TMEM39A (Affinity Capture-MS), ABCB10 (Affinity Capture-MS), POMT1 (Affinity Capture-MS), EDA (Affinity Capture-MS), PDE3B (Affinity Capture-MS), TM2D3 (Affinity Capture-MS), ZDHHC18 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GW64, A0A5F4BST2, A0PJX4, A8MVS5, A8MWV9, B0FP48, E5RIL1, E9PGG2, O14836, O60320, O95998, P09564, Q01113, Q01114, Q13477, Q2KI80, Q2T9R2, Q3TS39, Q3UPR0, Q3URD2, Q4V9L6, Q5FVJ4, Q5M869, Q6A044, Q6UWJ8, Q75VT8, Q864V4, Q8BRJ3, Q8BX43, Q8C503, Q8IVY1, Q8K5A9, Q8N112, Q8NC24, Q8NDY8, Q8QZT4, Q8R138, Q969Z4, Q9BUF7, Q9CQM1

Diamond homologs: P14753, P19235, P40931, Q01113, Q07303, Q2KL21, Q4W815, Q9MYZ9, Q01114, Q8R4S8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IL9	up-regulates	IL9R	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	2
Likely benign	4
Benign	27

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
147712	GRCh38/hg38 Xq28(chrX:155699559-156022206)x1	Pathogenic
154936	GRCh38/hg38 Xq28(chrX:155532532-156003229)x0	Pathogenic

SpliceAI

1604 predictions. Top by Δscore:

Variant	Effect	Δscore
X:156004551:G:GT	donor_gain	1.0000
X:156004552:A:T	donor_gain	1.0000
X:156004563:G:GT	donor_gain	1.0000
X:156004563:G:T	donor_gain	1.0000
X:156005430:GTGGA:G	donor_gain	1.0000
X:156005435:G:GG	donor_gain	1.0000
X:156006078:CACA:C	acceptor_loss	1.0000
X:156006081:AGGCC:A	acceptor_loss	1.0000
X:156006082:G:A	acceptor_loss	1.0000
X:156006082:GGCC:G	acceptor_gain	1.0000
X:156006187:AGGTA:A	donor_loss	1.0000
X:156006189:G:T	donor_loss	1.0000
X:156004418:A:AG	acceptor_gain	0.9900
X:156004419:G:GG	acceptor_gain	0.9900
X:156004419:GTT:G	acceptor_gain	0.9900
X:156004419:GTTA:G	acceptor_gain	0.9900
X:156004419:GTTAA:G	acceptor_gain	0.9900
X:156004526:C:G	donor_gain	0.9900
X:156004564:AGG:A	donor_loss	0.9900
X:156004565:GG:G	donor_loss	0.9900
X:156004566:GTAAC:G	donor_loss	0.9900
X:156004567:T:A	donor_loss	0.9900
X:156005276:A:AG	acceptor_gain	0.9900
X:156005276:AGCAG:A	acceptor_gain	0.9900
X:156005277:G:GG	acceptor_gain	0.9900
X:156005277:GCA:G	acceptor_gain	0.9900
X:156005277:GCAGG:G	acceptor_gain	0.9900
X:156005433:GA:G	donor_gain	0.9900
X:156006081:A:AG	acceptor_gain	0.9900
X:156006081:AG:A	acceptor_gain	0.9900

AlphaMissense

6814 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
Y:57191002:T:A	W166R	0.994
Y:57191002:T:C	W166R	0.994
Y:57191082:G:C	W192C	0.994
Y:57191082:G:T	W192C	0.994
Y:57191960:T:A	W248R	0.994
Y:57191960:T:C	W248R	0.994
Y:57191962:G:C	W248C	0.994
Y:57191962:G:T	W248C	0.994
Y:57190295:T:C	F118S	0.993
Y:57191064:G:C	K186N	0.992
Y:57191064:G:T	K186N	0.992
Y:57190074:T:C	F83S	0.991
Y:57190294:T:C	F118L	0.991
Y:57190296:C:A	F118L	0.991
Y:57190296:C:G	F118L	0.991
Y:57191004:G:C	W166C	0.990
Y:57191004:G:T	W166C	0.990
Y:57191954:A:C	S246R	0.990
Y:57191956:T:A	S246R	0.990
Y:57191956:T:G	S246R	0.990
Y:57190358:A:C	Y139S	0.989
Y:57190002:A:T	N59I	0.988
Y:57190357:T:C	Y139H	0.988
Y:57190358:A:G	Y139C	0.988
Y:57191953:G:C	W245C	0.987
Y:57191953:G:T	W245C	0.987
Y:57190295:T:G	F118C	0.986
Y:57190357:T:G	Y139D	0.986
Y:57191951:T:A	W245R	0.986
Y:57191951:T:C	W245R	0.986

dbSNP variants (sampled 300 via entrez): RS1000049770 (X:156006708 C>G,T), RS1000081875 (X:156006515 C>T), RS1000692372 (X:155998667 G>T), RS1000723453 (X:155998557 C>T), RS1000975891 (X:156003212 C>T), RS1001055953 (X:156007337 C>T), RS1001083528 (X:156007212 G>A,T), RS1001152216 (X:156001031 C>T), RS1001385243 (X:155996446 C>G), RS1001609180 (X:156011964 T>C), RS1001634917 (X:156000787 G>A), RS1001747496 (X:156005697 G>A,C), RS1001759127 (X:155996685 G>A), RS1002045700 (X:156011561 C>T), RS1002169709 (X:156005926 C>T)

Disease associations

OMIM: gene MIM:300007 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): male infertility (MONDO:0005372)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007248	Infertility, Male	C12.100.500.430; C12.100.750.700; C12.200.294.430

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-2 receptor family

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
pentanal	increases expression	1
CGP 52608	increases reaction, affects binding	1
poly(propyleneimine)	increases expression	1
Benzo(a)pyrene	increases expression	1
Cisplatin	increases expression	1
Mustard Gas	decreases expression	1
Smoke	decreases expression	1
Tetradecanoylphorbol Acetate	affects expression, affects cotreatment	1
Zinc	affects expression, affects cotreatment	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E8EJ	HEK-Blue IL-9	Transformed cell line	Female

Clinical trials (associated diseases)

125 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02202382	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Male Infertility
NCT02204826	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study
NCT03802864	PHASE4	COMPLETED	Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
NCT06100432	PHASE4	ACTIVE_NOT_RECRUITING	Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ β-carotene) for Infertile Males
NCT07523022	PHASE4	ENROLLING_BY_INVITATION	Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups
NCT00975117	PHASE3	COMPLETED	Spermotrend in the Treatment of Male Infertility
NCT01407432	PHASE3	COMPLETED	Impact of Folates in the Care of the Male Infertility
NCT01895816	PHASE3	COMPLETED	Herbal Tonic Fertile Supplement(ZO2C5)
NCT02605070	PHASE3	TERMINATED	Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia
NCT07402759	PHASE3	ACTIVE_NOT_RECRUITING	Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men
NCT01880086	PHASE2	COMPLETED	Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
NCT02061384	PHASE2	COMPLETED	RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02421887	PHASE2	COMPLETED	Males, Antioxidants, and Infertility Trial
NCT05200663	PHASE2	UNKNOWN	Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility
NCT05290558	PHASE2	ACTIVE_NOT_RECRUITING	The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial
NCT06091969	PHASE2	NOT_YET_RECRUITING	Supplementation for Male Subfertility
NCT01595308	PHASE1	COMPLETED	A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers
NCT02122211	PHASE1	COMPLETED	Choline Dehydrogenase and Sperm Function: Effects of Betaine
NCT02575924	PHASE1	UNKNOWN	Influence of Culture Media on Clinical Outcomes in Poor Responders or Severe Male Infertility
NCT01304927	PHASE2/PHASE3	COMPLETED	Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial
NCT02349945	PHASE2/PHASE3	COMPLETED	FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy
NCT05222841	PHASE2/PHASE3	COMPLETED	The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
NCT05616598	PHASE2/PHASE3	COMPLETED	Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
NCT02025270	PHASE1/PHASE2	COMPLETED	MSCs For Treatment of Azoospermic Patients
NCT04541459	EARLY_PHASE1	UNKNOWN	Validation of New Devices Against Ambient Electromagnetic Radiation
NCT05792813	EARLY_PHASE1	UNKNOWN	Efficacy and Safety of Linggui Yangyuan Paste in Patients With Male Infertility
NCT06188936	EARLY_PHASE1	COMPLETED	Home Semen Analysis Tests As a Screening Tool for Fertility Patients
NCT00012480	Not specified	COMPLETED	Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm
NCT00044369	Not specified	COMPLETED	Role of the Toxic Metal Cadmium in the Mechanism Producing Infertility With a Varicocele
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists
NCT00178516	Not specified	COMPLETED	Vitamin E and Male Infertility
NCT00315029	Not specified	COMPLETED	Patient-Centered Implementation Trial for Single Embryo Transfer
NCT00341120	Not specified	COMPLETED	Genetic Causes of Male Infertility
NCT00481403	Not specified	COMPLETED	Study of Sperm Molecular Factors Implicated in Male Fertility
NCT00548977	Not specified	COMPLETED	Genetic Studies Spermatogenic Failure
NCT00596739	Not specified	COMPLETED	A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery
NCT00756561	Not specified	COMPLETED	HOP-2A - Intratesticular Hormone Levels
NCT00961558	Not specified	TERMINATED	Canadian Varicocelectomy Initiative (CVI): Effects on Male Fertility and Testicular Function of Varicocelectomy
NCT01075334	Not specified	UNKNOWN	Is a Carnitine Based Food Supplement (PorimoreTM) for Infertile Men Superior to Folate and Zinc With Regard to Pregnancy Rates in Intrauterine Insemination Cycles?
NCT01178463	Not specified	UNKNOWN	Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia